The Ibn Sina Pharmaceutical Industry PLC introduces Dexlan MUPS 30 mg, an advanced Dual Delayed-Release (DDR) Multi-Unit Pellet System designed for superior, 24-hour acid control in patients with symptomatic non-erosive GERD and maintained healing of Erosive Esophagitis. Engineered with uniform micro-pellets, Dexlan MUPS disintegrates rapidly in the stomach to prevent localized mucosa irritation and dose-dumping, delivering a biphasic release profile that guarantees consistent plasma concentrations regardless of meal timing. Positioned as a hassle-free, highly predictable step-down and maintenance therapy, this once-daily formulation offers clinicians an optimized option for long-term GERD management with maximum patient compliance and round-the-clock symptom relief.

null

null

Ezygo (Sodium Picosulfate) is a tri-aryl-methane group derivative stimulant laxative. After oral administration it is activated by the colonic bacteria and acts locally in the colon. The active form then stimulates the nerve endings of the intestinal wall and results in colonic peristalsis with promotion of accumulation of water and electrolytes in the colonic lumen. This results in stimulation of defecation, reduction of transit time and softening of the stool. Stimulation of the rectum causes increased motility and a feeling of rectal fullness. The rectal effect may help to restore the "call to stool".